Review of NICE Technology Appraisal Guidance No. 208; Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

The Institute was proposing that the guidance should be moved to the static list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

TA208 will consequently be moved to the static list.  Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

October 2013